After reaching a multimillion-dollar settlement with drug companies in October that averted the first trial over the opioid crisis, lead plaintiffs lawyers are gearing up for the next trial: this time, against six pharmacies including Walgreens and CVS.

Ahead of that trial, the pharmacies, however, have revived concerns about judicial conduct in the opioid litigation.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]